MedTrace Logo

Trends in the Administration of Tranexamic Acid for Postpartum Hemorrhage

NCT07278037 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 648

Last updated 2025-12-22

No results posted yet for this study

Summary

Postpartum hemorrhage (PPH) is the global leading cause of maternal death, with 20-30% of maternal deaths in Thailand linked to hemorrhage. The WOMAN Trial (2017) provided strong evidence that administering tranexamic acid (TXA)within three hours of bleeding onset lowered PPH-related mortality by 31%. Consequently, the World Health Organization (WHO) updated its guidelines, recommending TXA as part of the standard treatment package for all PPH cases. Following this, the use of TXA has been widely adopted globally and increased in Thailand. A recent study at a major Thai university hospital observed a significant increase in TXA administration after 2017. The current study aims to further analyze the recent growth rate of TXA use and its impact on obstetric and perinatal outcomes during cesarean deliveries with PPH.

Conditions

  • Postpartum Hemorrhage
  • Delivery Complication
  • Cesarean Section Complications
  • Perinatal Problems

Interventions

DRUG

Tranexamic acid

The number of patients received tranexamic acid after postpartum hemorrhage

Sponsors & Collaborators

  • Mahidol University

    lead OTHER

Principal Investigators

  • Patchareya Nivatpumin, M.D. · Siriraj Hospital

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-01
Primary Completion
2026-03-31
Completion
2026-09-30

Countries

  • Thailand

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07278037 on ClinicalTrials.gov